Keyword Analysis & Research: incyte
Keyword Research: People who searched incyte also searched
Search Results related to incyte on Search Engine
-
Biopharmaceutical Company | Solutions for Unmet Medical Needs | Incyte…
https://incyte.com/
WEBA source for information and support. Incyte is a global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines..
DA: 69 PA: 90 MOZ Rank: 2
-
Incyte - Wikipedia
https://en.wikipedia.org/wiki/Incyte
WEBIncyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware, and Morges, Switzerland. The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991 and Incyte Genomics, Inc. of Delaware.
DA: 26 PA: 7 MOZ Rank: 17
-
Global Biopharmaceutical Company | Incyte.com
https://incyte.com/who-we-are/biopharmaceutical-research
WEBWHAT WE DO. Incyte is a global biopharmaceutical company that has created a robust and diversified portfolio of marketed products and clinical candidates in oncology, inflammation, and autoimmunity.
DA: 12 PA: 77 MOZ Rank: 37
-
Incyte Leadership | Incyte.com
https://incyte.com/our-company/our-leadership
WEBExecutive Vice President and General Counsel. Sheila A. Denton joined Incyte in 2023 as Executive Vice President and General Counsel, with more than 30 years of legal, policy and compliance experience across the biopharmaceutical, pharmaceutical and animal health …
DA: 70 PA: 23 MOZ Rank: 94
-
Portfolio: MPNs & GVHD, Hematology/Oncology, Dermatology ... - Incyte
https://incyte.com/what-we-do/pharmaceutical-portfolio
WEBFeb 13, 2024 · Explore Our Science. We have a breadth of clinical programs within our portfolio across Myeloproliferative Neoplasms (MPNs) and Graft-Versus-Host Disease (GVHD), General Hematology/Oncology, Dermatology and other Inflammation & Autoimmunity (IAI), and Partnered Programs.
DA: 95 PA: 33 MOZ Rank: 15
-
Oncology Research | Targeted & Immunotherapy For Cancer | Incyte…
https://incyte.com/what-we-do/oncology
WEBIncyte is a leader in the discovery and development of therapies for patients with myeloproliferative neoplasms (MPNs) and graft-versus-host disease (GVHD). We have multiple clinical trials evaluating monotherapy and combination strategies to improve and expand treatments for patients with MPNs and GVHD.
DA: 24 PA: 27 MOZ Rank: 16
-
Incyte Corporation (INCY) - Yahoo Finance
https://finance.yahoo.com/quote/INCY
WEB1.3200. -2.94%. Find the latest Incyte Corporation (INCY) stock quote, history, news and other vital information to help you with your stock trading and investing.
DA: 67 PA: 92 MOZ Rank: 78
-
Investors | Incyte
https://investor.incyte.com/
WEBApr 1, 2024 · Investors. Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives.
DA: 67 PA: 100 MOZ Rank: 85
-
Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) …
https://investor.incyte.com/news-releases/news-release-details/incyte-announces-fda-approval-zynyztm-retifanlimab-dlwr
WEBMar 22, 2023 · PDF Version. — First regulatory approval for Incyte PD-1 inhibitor based on the results of the POD1UM-201 trial. — Zynyz is also being studied in additional tumor types and in combination with other Incyte pipeline compounds.
DA: 60 PA: 99 MOZ Rank: 44
-
Drug Development & Scientific Innovation in Oncology and ... - Incyte
https://incyte.com/what-we-do/drug-development
WEBIncyte’s team of biologists and chemists are pursuing new areas in drug discovery and development in order to help patients. Drug Development & Scientific Innovation in Oncology and Inflammation & Autoimmunity | Incyte.com
DA: 47 PA: 60 MOZ Rank: 90
